Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

U.K. advice for codeine products

This article was originally published in The Tan Sheet

Executive Summary

The U.K.'s Medicines and Healthcare products Regulatory Agency bolsters its labeling and packaging advice for manufacturers of OTC pain relief products with codeine or dihydrocodeine. In a Sept. 2 1letter to industry and pharmacists, the agency recommends warnings about overuse of the drugs be moved to the front of packaging and that codeine/DHC products be capped at 32-count size. Previous voluntary label and packaging changes for the products instituted in 2005 "have not proved effective" in reducing overuse, MHRA notes (2"The Tan Sheet" Aug. 22, 2005). The Proprietary Association of Great Britain, representing OTC manufacturers, said Sept. 3 it supports the advice recommended by MHRA's Commission on Human Medicines and its member companies already restrict codeine/DHC product packs to 32 tablets. MHRA's advice applies to U.K. OTC brands including Reckitt Benckiser's Nurofen Plus and GlaxoSmithKline's Panadol Ultra and Solpadeine Max, PAGB said

You may also be interested in...



UK Strengthens Addiction Warnings For Nonprescription Codeine Products

Warnings that long-term use of codeine and/or dihydrocodeine may lead to addiction will be added to product labeling for nonprescription analgesics that contain the ingredients, the Medicine & Healthcare products Regulatory Agency announced Aug. 15

GeNeuro To Tackle Long COVID By Targeting Ancestor Viral Gene Activation

Switzerland’s GeNeuro will study whether its monoclonal antibody temelimab can prevent long-COVID, after data for the first time linked activation of human endogenous retroviruses (HERVs) to the condition and its associated neurological symptoms.

Executives On The Move: CFO Promoted At Novavax, Gilead Gets New Executive Vice President Of Research

Alpha Cognition, F2G and Immune Pharmaceuticals pick up new CEOs, and there is a new chief medical officer at Gemini Therapeutics.

Topics

UsernamePublicRestriction

Register

PS103309

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel